UTC Aerospace Systems Selected by Xiamen Airlines to Provide Wheels and Carbon Brakes on Boeing 787-8 Fleet

Posted on by

CHARLOTTE, N.C., Oct. 9, 2013 /PRNewswire/ -- UTC Aerospace Systems has been selected by Xiamen Airlines to supply the wheels and carbon brakes for its fleet of 6 new Boeing 787-8 aircraft. The company will provide the equipment through its Wheels & Brakes business in Troy, Ohio. The first aircraft is scheduled for delivery in July 2014. UTC Aerospace Systems is a unit of United Technologies Corp. (UTX).

The 787-8 carbon brakes use proprietary DURACARB(R) carbon heat sink material. The DURACARB(R) carbon provides exceptional brake performance and a 35 percent brake life advantage over competitive products, producing significant costs savings for operators.

"We are pleased to enter into a new business relationship with Xiamen Airlines on the 787-8 program," said Cory May, vice president of commercial programs, Wheels & Brakes. "We look forward to providing Xiamen with a superior level of customer support for their 787 fleet and entry into service."

Tang Jianqi, General Manager of Xiamen Airlines Maintenance & Engineering Division stated, "Due to the new technology of the 787 electric brake, electro-mechanical braking experience was a critical factor in our supplier selection. We have confidence that UTC Aerospace Systems will provide us their 787 electric brake products with the highest in performance and reliability."

Established on July 25, 1984 and based in Xiamen, Xiamen Airlines operates the majority of its scheduled passenger flights out of Xiamen Gaoqi International Airport. The Airline is owned by China Southern Airlines (51%), Xiamen Construction and Development Group (34%) and Jizhong Energy Group (15%).

UTC Aerospace Systems designs, manufactures and services integrated systems and components for the aerospace and defense industries. It is a worldwide leader in electro-mechanical aircraft brakes with over fifteen years of experience. UTC Aerospace Systems supports a global customer base with significant worldwide manufacturing and customer service facilities.

United Technologies Corp., based in Hartford, Connecticut, is a diversified company providing high-technology products and services to the building and aerospace industries.

http://www.utcaerospacesystems.com

More here:

UTC Aerospace Systems Selected by Xiamen Airlines to Provide Wheels and Carbon Brakes on Boeing 787-8 Fleet

Aerospace & Defense Stocks Weaken on Back of Government Shutdown, Fed Comments

Posted on by

Aerospace and defense stocks fell Wednesday, with the S&P Aerospace & Defense Select Industry Index (SPSIAD) down 0.4%, on continued concern over the impact of the government shutdown, as the sector relies on government contracts.

Investors were also concerned by comments from Charles Evans, president and chief executive of the Federal Reserve Bank of Chicago, highlighting continued high jobless rates and disappointing U.S. economic growth.

The sector's decliners included Boeing Co. ( BA ), down 0.7%; Spirit AeroSystems Holdings Inc. ( SPR ), down 1.3%; Textron Inc. ( TXT ), down 1.1%; and General Dynamics Corp. ( GD ), down 0.1%.

AAR Corp. ( AIR ) bucked the downward trend, rising 0.6% as the company held its annual shareholder meeting.

SPSIAD is up 30% year to date, versus the S&P 500's 16% climb.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.

Continued here:

Aerospace & Defense Stocks Weaken on Back of Government Shutdown, Fed Comments

Harper Government Affirms Support for Saskatchewan Aerospace and Defence Sector

Posted on by

SASKATOON, SASKATCHEWAN--(Marketwired - Oct 9, 2013) - Today, the Honourable Michelle Rempel, Minister of State for Western Economic Diversification, addressed the Saskatchewan Aerospace and Defence Opportunities Forum regarding the opportunities available for Saskatchewan companies to advance their businesses in these important sectors.

"Through our Government's Industrial and Regional Benefits Policy, we are ensuring that Canadian companies have access to high quality business opportunities by leveraging Canada's military procurements," said Minister Rempel. "Today's forum will position Saskatchewan companies to capitalize on the many opportunities available in these sectors."

WD has made significant investments in projects and initiatives that support Western Canada's aerospace, defence and, shipbuilding industries. These investments have improved the technology and equipment in these sectors by making them safer and more productive, resulting in new opportunities, jobs, and training and research benefits for industry across the West.

The Saskatchewan Aerospace and Defence Opportunities Forum provides western Canadian aerospace, defence, security and marine companies the opportunity to establish new relationships and pursue new business ventures. Western Economic Diversification Canada (WD) and the Saskatchewan Ministry of Economy partnered with the Saskatchewan Aviation Council to host this event.

Since 2006, the Harper Government, through WD, has invested in job-creating small- and medium-sized businesses, aerospace, marine and defence industries, and supported innovative entrepreneurs in pursuing emerging markets. By continuing to promote new economic opportunities, WD is helping to create jobs, economic growth, and long-term prosperity.

Subscribe to news releases and keep up-to-date on the latest from WD or Follow us on Twitter.

The West Means Business.

Here is the original post:

Harper Government Affirms Support for Saskatchewan Aerospace and Defence Sector

2013 Nobel Prize in Physiology or Medicine: Discoveries of machinery regulating vesicle traffic in cells

Posted on by

Oct. 7, 2013 The Nobel Assembly at Karolinska Institutet has today decided to award The 2013 Nobel Prize in Physiology or Medicine jointly to James E. Rothman, Randy W. Schekman and Thomas C. Sdhof for their discoveries of machinery regulating vesicle traffic, a major transport system in our cells.

Summary

The 2013 Nobel Prize honors three scientists who have solved the mystery of how the cell organizes its transport system. Each cell is a factory that produces and exports molecules. For instance, insulin is manufactured and released into the blood and chemical signals called neurotransmitters are sent from one nerve cell to another. These molecules are transported around the cell in small packages called vesicles. The three Nobel Laureates have discovered the molecular principles that govern how this cargo is delivered to the right place at the right time in the cell.

Randy Schekman discovered a set of genes that were required for vesicle traffic. James Rothman unravelled protein machinery that allows vesicles to fuse with their targets to permit transfer of cargo. Thomas Sdhof revealed how signals instruct vesicles to release their cargo with precision.

Through their discoveries, Rothman, Schekman and Sdhof have revealed the exquisitely precise control system for the transport and delivery of cellular cargo. Disturbances in this system have deleterious effects and contribute to conditions such as neurological diseases, diabetes, and immunological disorders.

How cargo is transported in the cell

In a large and busy port, systems are required to ensure that the correct cargo is shipped to the correct destination at the right time. The cell, with its different compartments called organelles, faces a similar problem: cells produce molecules such as hormones, neurotransmitters, cytokines and enzymes that have to be delivered to other places inside the cell, or exported out of the cell, at exactly the right moment. Timing and location are everything. Miniature bubble-like vesicles, surrounded by membranes, shuttle the cargo between organelles or fuse with the outer membrane of the cell and release their cargo to the outside. This is of major importance, as it triggers nerve activation in the case of transmitter substances, or controls metabolism in the case of hormones. How do these vesicles know where and when to deliver their cargo?

Traffic congestion reveals genetic controllers

Randy Schekman was fascinated by how the cell organizes its transport system and in the 1970s decided to study its genetic basis by using yeast as a model system. In a genetic screen, he identified yeast cells with defective transport machinery, giving rise to a situation resembling a poorly planned public transport system. Vesicles piled up in certain parts of the cell. He found that the cause of this congestion was genetic and went on to identify the mutated genes. Schekman identified three classes of genes that control different facets of the cells transport system, thereby providing new insights into the tightly regulated machinery that mediates vesicle transport in the cell.

Docking with precision

Read this article:
2013 Nobel Prize in Physiology or Medicine: Discoveries of machinery regulating vesicle traffic in cells

Got beer? Thank a microbiologist

Posted on by

Beauty and the yeast

Rebecca Newman, quality control manager with Dogfish Head Craft Brewery says the microbiology of yeast is crucial to a beer's taste. (4:02)

Download

WASHINGTON - A beer drinker looking to quench his thirst might not give a second thought to what microbiologists call "the master ingredient" in beer.

"I think the typical consumer doesn't really think about the yeast, but if it goes wrong they'll definitely know it was a yeast problem," says Rebecca Newman, quality control manager for Dogfish Head Craft Brewery.

Newman was recruited by Anheuser-Busch right out of college in the mid-'80s, armed with a degree in food science and technology.

She and Charlie Bamforth, Ph.D., Anheuser-Busch Endowed Professor of Malting and Brewing Sciences, University of California - Davis, will be speaking Thursday evening at the headquarters of the American Society for Microbiology, in an event called "The Microbiology of Beer."

The American Academy of Microbiology produced a report entitled "If the yeast ain't happy, ain't nobody happy."

"I look at yeast as being the conductor of an orchestra, with all the ingredients as the instruments that would go into making the different beers," says Newman.

And I look at the yeast as conducting all those ingredients to come up with a final beer flavor," says Newman.

See the article here:
Got beer? Thank a microbiologist

PathoGenetix Research Shows Rapid Identification of Multiple Salmonella Serovars in Food Samples

Posted on by

Woburn, MA (PRWEB) October 09, 2013

PathoGenetix, Inc., a commercial-stage developer of an automated system for rapid bacterial identification, will present new research today demonstrating the use of Genome Sequence Scanning (GSS) technology to confirm and identify multiple serovars of Salmonella in enriched food samples in less than five hours. The data, included in a poster presentation at the 4th American Society for Microbiology (ASM) Conference on Salmonella in Boston, add to a growing body of research demonstrating the use of PathoGenetixs proprietary genotyping technology to reliably identify pathogens of public health and food safety significance, including Salmonella and Shiga toxin-producing E. coli (STECs).

The study evaluated the use of GSS in molecular serotyping and sub-typing of Salmonella, and as a tool for simultaneous detection of multiple serovars of Salmonella in complex mixtures. The study results show that GSS can be used to infer the serotype of an unknown Salmonella strain, based on the location of the strain on the GSS tree and the identity of its neighbors. The results also demonstrate the ability of GSS to shorten the time to just five hours for pathogen subtyping and serotype determination from an enriched food sample, including those containing multiple serovars.

Because Genome Sequence Scanning is culture independent, and fully automated from sample preparation to final report, the technology greatly reduces the time, complexity and skill required when compared to other molecular and next generation sequencing (NGS) identification approaches. The strain-type information provided by GSS is comparable to pulsed field gel electrophoresis (PFGE), the current standard for pathogen typing in foodborne outbreak investigation and response. As a result, GSS offers a powerful new tool for epidemiological investigations and outbreak monitoring that can enable quicker decisions affecting food safety and public health. The GSS technology will be commercially available in 2014 in the RESOLUTION Microbial Genotyping System.

According to the American Society of Microbiology, Salmonella infections continue to be a major public health problem in many parts of the world. In the U.S., Salmonella is the leading cause of foodborne illnesses leading to hospitalization and death. The Salmonella genus has more than 2,500 serotypes or serovars, based on the antigens that the organism presents on its surface. In the U.S., Salmonella Enteritidis and Salmonella Typhimurium are the most common serotypes, accounting for half of all Salmonella infections in people.

The 4th ASM Conference on Salmonella brings together scientists from a variety of backgrounds to present the most recent research and discoveries in the field, including new approaches in diagnosis, treatment and prevention of infections. PathoGenetixs research, entitled Evaluation of Genome Sequence Scanning technology for molecular (sub)-serotyping of Salmonella and simultaneous detection of multiple Salmonella serovars in complex mixtures is being presented in a poster session on October 9.

The research tested the strain typing capability of GSS using more than 400 strains and genome sequences representing the most frequently encountered Salmonella serovars from food products associated with human illness. The results show that Genome Sequence Scanning clustered Salmonella strains into serovar-specific branches on the GSS tree, clearly demarcating the major serovars from each other. Polyphyletic lineage serovars like S. Newport and S. Saintpaul formed more than one distinctly separated branch on the tree, reflecting the genetic heterogeneity within these serovars. GSS assigned correct serovar designations to strains untypeable by conventional serotyping and to antigenic variants of serovars based on genetic similarity. Genome Sequence Scanning also reliably detected the presence of up to three different serovars of Salmonella in the presence of complex background flora, demonstrating the technologys ability to provide strain information directly from complex mixtures.

***

About PathoGenetix, Inc.

PathoGenetix, Inc. is a commercial-stage developer of an automated system for rapid bacterial identification from complex samples. PathoGenetix is a venture-backed company that has received more than $50 million in technology development funding from the Department of Homeland Security. The core Genome Sequence Scanning (GSS) technology analyzes DNA from an enriched biological samplewithout the need for a cultured isolateand provides results in five hours. GSS has broad applicability in food safety, industrial microbiology, and clinical diagnostics and research. The GSS technology will be available in the RESOLUTION Microbial Genotyping System in 2014 for use in food safety testing and foodborne illness outbreak investigations. Learn more at http://www.pathogenetix.com.

Read more:
PathoGenetix Research Shows Rapid Identification of Multiple Salmonella Serovars in Food Samples

Schekman, Sudhof Awarded 2013 Nobel Prize in Physiology or Medicine

Posted on by

Newswise The Royal Swedish Academy of Sciences announced today that Randy W. Schekman, a Howard Hughes Medical Institute (HHMI) investigator at the University of California, Berkeley, Thomas C. Sdhof, an HHMI investigator at Stanford University, and James E. Rothman of Yale University are the recipients of the 2013 Nobel Prize in Physiology or Medicine for their discoveries of machinery regulating vesicle traffic, a major transport system in our cells.

According to the Royal Swedish Academy, this year's Nobel Prize in Physiology or Medicine honors three scientists who have solved the mystery of how the cell organizes its transport system. Each cell is a factory that produces and exports molecules. For instance, insulin is manufactured and released into the blood and chemical signals called neurotransmitters are sent from one nerve cell to another. These molecules are transported around the cell in small packages called vesicles. The three Nobel Laureates have discovered the molecular principles that govern how this cargo is delivered to the right place at the right time in the cell.

Schekman discovered a set of genes that were required for vesicle traffic. Rothman unraveled protein machinery that allows vesicles to fuse with their targets to permit transfer of cargo. Sdhof revealed how signals instruct vesicles to release their cargo with precision.

Through their discoveries, Rothman, Schekman and Sdhof have revealed the exquisitely precise control system for the transport and delivery of cellular cargo. Disturbances in this system have deleterious effects and contribute to conditions such as neurological diseases, diabetes, and immunological disorders.

Randy W. Schekman

Traffic inside a cell is as complicated as rush hour near any metropolitan area. But drivers know how to follow the signs and roadways to reach their destinations. How do different cellular proteins "read" molecular signposts to find their way inside or outside of a cell?

For the past three decades, Randy Schekman has been characterizing the traffic drivers that shuttle cellular proteins as they move in membrane-bound sacs, or vesicles, within a cell. His detailed elucidation of cellular travel patterns has provided fundamental knowledge about cells and has enhanced understanding of diseases that arise when bottlenecks impede some of the protein flow. Schekman has been an HHMI investigator since 1991. He also serves as editor-in-chief of the open access research journal eLife.

His work earned him one of the most prestigious prizes in science, the Albert Lasker Award for Basic Medical Research, which he shared with James Rothman in 2002.

Schekman's path to award-winning researcher began with a youthful enthusiasm for science and math, which he attributes to his father, an engineer who helped develop the first online program for real-time stock quotes. High school science fairsand winning themfurther whetted his appetite for competitive science. Biology's power hit him more personally, though, when his teenage sister died of leukemia.

He considered pursuing medical school as an undergraduate at the University of California, Los Angeles. But after spending his junior year in a laboratory at the University of Edinburgh, his path to graduate school became set. He obtained a Ph.D. in biochemistry at Stanford in the laboratory of Arthur Kornberg, who won the Nobel Prize in 1959 for identifying a key enzyme in DNA synthesis.

Here is the original post:
Schekman, Sudhof Awarded 2013 Nobel Prize in Physiology or Medicine

3 U.S.-based scientists win Nobel in physiology or medicine

Posted on by

Three scientists who study the inner workings of cells have won the 2013 Nobel Prize in physiology or medicine for their work in unraveling the mystery of how proteins, hormones and other molecules are moved around inside cells and exported to other parts of the body.

The Nobel committee lauded Randy W. Schekman of UC Berkeley, Thomas C. Suedhof of Stanford University and James E. Rothman of Yale University for making known "the exquisitely precise control system for the transport and delivery of cellular cargo. Disturbances in this system have deleterious effects and contribute to conditions such as neurological diseases, diabetes and immunological disorders."

The announcement was made Monday in Stockholm.

"It's a fundamental discovery of cell physiology, and it was not entirely easy for these investigators when they started," Juleen Zierath, chairwoman of the committee that awarded the prize, said in an interview posted on the Nobel website.

For decades, the three molecular and cellular biologists have studied the cell's intricate internal transport system in which bubble-like vesicles shuttle key molecules including neurotransmitters and enzymes to different parts of the cell and through the cell's membrane.

"Think of a cell as sort of a factory, and it needs to produce proteins," said Zierath, a professor in clinical integrative physiology at the Karolinska Institute in Sweden. Cells "need to shuttle these proteins and cargo from one workstation to the next, so each protein can get a little bit better refined along the way."

The researchers had been considered among the top contenders for the award, which is worth about $1.2 million. Schekman and Rothman were joint winners of the prestigious Albert Lasker Basic Medical Research Award in 2002, and Suedhof was recognized with the award last month.

At a news conference in Berkeley, Schekman said he was aware of the speculation but didn't think he would win.

But hours after returning from an award ceremony in Germany, the 64-year-old was awakened at 1:30 a.m. by a ringing phone and his wife, Nancy, shouting, "This is it! This is it!"

"My heart was pounding and I was trembling," Schekman said. "But then I heard a comforting voice with a thick Swedish accent congratulating me."

More:
3 U.S.-based scientists win Nobel in physiology or medicine

Carmel Valley mom heads growing full-service microbiology laboratory

Posted on by

By Kristina Houck

Kim Lim at Ultimate Labs / Courtesy photo

Kim Lim saw the need for a company in San Diego that offered a variety of laboratory services. Although she was a new single parent and the country was in the midst of a recession, the Carmel Valley woman decided to fill that need by founding Ultimate Labs in 2008.

The full-service microbiology laboratory provides environmental monitoring, microbial water and food testing to the pharmaceutical, biotechnology, medical device and food industries.

It was extremely difficult, said founder and CEO Lim, who has lived in the community for about 15 years. There wasnt a lot of funding or outside help with the banking industry, so we really bootstrapped it. Its really my own personal investment.

Ultimate Labs opened its doors with four employees and 10 clients. It has since grown to nearly 20 staff members and more than 200 clients across the United States.

The company, which was recently named one of the Best Places to Work by the San Diego Business Journal, offers the latest laboratory technology. In fact, it recently acquired the Vitek Mass Spec system to provide clients with the most rapid mass spectrometry method available to detect microbial pathogens in food and pharmaceutical production. Ultimate Labs is one of only two laboratories with the equipment, with the other on the East Coast.

Were always striving to be more innovative and be problem solvers rather than just a testing service, so I think that is why weve grown so much, Lim said. Were really looking for solutions for our clients as opposed to just doing cookie-cutter testing.

Before founding Ultimate Labs, Lim worked as an engineering consultant in the biotech industry for more than a decade. Originally from Boston, she came to San Diego as a traveling consultant.

Shortly after the birth of her son, Lim divorced. She once again became a consultant before she decided to launch her own business. She also adopted her second son.

Excerpt from:
Carmel Valley mom heads growing full-service microbiology laboratory

Leishmania parasites with greater infectivity associated with treatment failure

Posted on by

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Jim Sliwa jsliwa@asmusa.org 202-942-9297 American Society for Microbiology

Relapses after treatment for Leishmania infection may be due to a greater infectivity of the parasite rather than drug resistance, as has been previously thought, according to a study published in mBio, the online open-access journal of the American Society for Microbiology.

Visceral leishmaniasis, also called kala-azar, is a parasitic disease that strikes 400,000 people every year and kills around 1 in 10 of its victims. The disease has proven difficult to treat, in part because a large percentage of patients who take the drug of choice, miltefosine, relapse after treatment, coming down with the same disease all over again. Doctors and scientists have long suspected that drug resistance was behind the failure of miltefosine, but that's not so, according to the researchers. The study reveals that parasites in patients who relapse after leishmaniasis treatment have a greater infectivity than parasites from patients who were treated successfully. They are essentially a worse, more dangerous form of the parasite.

"Parasites from relapsed patients show an increased capacity to infect host cells," says co-author Manu Vanaerschot of the Institute of Tropical Medicine in Antwerp,Belgium. The authors write that it remains to be seen whether miltefosine treatment causes the increased infectivity of the parasite, or if parasites with greater infectivity are capable of escaping treatment.

Miltefosine is at the heart of a vast program aimed at ending visceral leishmaniasis on the Indian subcontinent (India, Bangladesh and Nepal), but 6.8% of Indian patients redevelop symptoms of the disease within 6 months after treatment and 20% of Nepalese patients relapse within 12 months after miltefosine treatment. Parasites collected from patients before and after treatment have been fingerprinted and are very close genetic matches, indicating that these patients are not simply re-infected with new parasites once their treatment ends, they are still carrying the same strain that sickened them before treatment. Other work revealed another surprising fact: parasites from relapsed patients were sensitive to miltefosine, so the failure of treatment was not due to drug resistance, a common suspect in cases where infectious disease treatment fails.

With re-infection and drug resistance now crossed off the list of possible reasons for the high relapse rate, the researchers set out to see what factors might really be at work. They examined the morphology of parasites taken from visceral leishmaniasis patients who were treated successfully and patients who relapsed. They found a significant association between the number of parasites in the metacyclic stage of their life cycle and patient treatment outcome. In other words, patients who relapsed were infected with parasites that have a greater infectivity, meaning they were more capable of infecting human cells.

The precise link between infectivity and treatment failure is not known, write the authors, but they propose that parasites with greater infectivity might cause a greater parasite load in the patient, making the case more difficult to treat, or perhaps they are able to evade the drug by hiding in parts of the body it doesn't easily penetrate, like the skin.

Vanaerschot says he and his colleagues saw a similar correlation between infectivity and treatment failure in patients who had been treated with the types of drugs that used to be favored in the region, pentavalent animonials. "At the time we thought that it was a very special case. But now that we've also seen this in parasites treated with other drugs, this indicates that it might be a more common problem than we originally thought."

Co-author Jean-Claude Dujardin, of the Institute of Tropical Medicine and the University of Antwerp, in Belgium, says regardless of the underlying cause-and-effect relationship, the findings are a wake-up call about the possible effects a therapy might have on pathogens it's supposed to kill.

Go here to read the rest:
Leishmania parasites with greater infectivity associated with treatment failure

Loss of anti-aging gene possible culprit in age-related macular degeneration

Posted on by

Public release date: 8-Oct-2013 [ | E-mail | Share ]

Contact: Karen Mallet km463@georgetown.edu Georgetown University Medical Center

WASHINGTON A team of researchers at Georgetown University Medical Center (GUMC) has found that loss of an anti-aging gene induces retinal degeneration in mice and might contribute to age-related macular degeneration, the major cause of blindness in the elderly.

In the Oct. 9 issue of the Journal of Neuroscience, the scientists demonstrated a key role for the aging-suppressor gene Klotho in maintaining the health of the mouse and human retina. They say that in their animal studies, loss of Klotho expression leads to characteristics observed in both kinds of macular degeneration wet and dry seen in humans.

Klotho, a hormone that is synthesized and secreted by some organs and tissues, is being studied worldwide for its anti-aging properties. A Japanese researcher discovered 15 years ago that when Klotho is mutated, a mouse that should live two years survives for only two months. Transgenic mice that overexpress the Klotho gene have a longer-than-expected lifespan.

"We found four important functions Klotho provides in the human retina, which leads us to believe that the gene is crucial to the health of this light sensitive tissue," says the study's senior investigator, Nady Golestaneh, PhD, assistant professor of ophthalmology, neurology, biochemistry and molecular & cellular biology at GUMC.

They found that Klotho increases the activity of genes that synthesize the light absorbing visual pigments in the retinal cells. Klotho also increases the expression of genes that protect against the oxidative stress known to damage the retina, and which can lead to dry macular degeneration. Klotho inhibits the vascular endothelial growth factor and therefore, might play an important role in inhibiting the overgrowth of blood vessels in the eye, a major cause of wet macular degeneration.

Klotho also regulates phagocytosis of the outer segment of photoreceptors in the retina. This process allows the photoreceptors to renew themselves, and if that function is abolished, the photoreceptors degenerate and die causing blindness.

"For these reasons, we believe Klotho might be an interesting therapeutic target for age-related macular degeneration," Golestaneh says. "Gene therapy or cell therapy might be able to induce new expression of Klotho in the aging retina."

But she adds that before these strategies can be tested, research that quantifies the decline of Klotho expression in human eyes, and directly links this dysfunction to macular degeneration, must be undertaken.

Visit link:
Loss of anti-aging gene possible culprit in age-related macular degeneration

Purtier Placenta Live stem Cell Therapy Miracle – Mr Wilson Grandma is healthy now after 8 months – Video

Posted on by


Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months
This video is from YouTube Channel-wilsonho ho. In his YouTube Wilson never mentions much. Just a short message, My grandmother is healthy now after 8months ...

By: Purtier Placenta Singapore Original

Read more:

Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months - Video